share_log

UBS Maintains Neutral on BioNTech, Raises Price Target to $131

Benzinga ·  Sep 18 21:14  · Ratings

UBS analyst Eliana Merle maintains BioNTech (NASDAQ:BNTX) with a Neutral and raises the price target from $97 to $131.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment